{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T20:51:18Z","timestamp":1775163078417,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12883-017-0927-x","type":"journal-article","created":{"date-parts":[[2017,8,7]],"date-time":"2017-08-07T05:44:15Z","timestamp":1502084655000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Outcome of MS relapses in the era of disease-modifying therapy"],"prefix":"10.1186","volume":"17","author":[{"given":"Muriel","family":"Stoppe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Busch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luise","family":"Krizek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Then Bergh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,8,7]]},"reference":[{"issue":"Pt 6","key":"927_CR1","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1093\/brain\/112.6.1419","volume":"112","author":"BG Weinshenker","year":"1989","unstructured":"Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain. 1989;112(Pt 6):1419\u201328.","journal-title":"Brain"},{"issue":"Pt 3","key":"927_CR2","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/brain\/120.3.393","volume":"120","author":"B Ferguson","year":"1997","unstructured":"Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain. 1997;120(Pt 3):393\u20139.","journal-title":"Brain"},{"key":"927_CR3","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1136\/jnnp.50.5.511","volume":"50","author":"NM Milligan","year":"1987","unstructured":"Milligan NM, Newcombe R, Compston DA. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1 clinical effects. J Neurol Neurosurg Psychiatry. 1987;50:511\u20136.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"927_CR4","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s001150170057","volume":"72","author":"O Grauer","year":"2001","unstructured":"Grauer O, Offenh\u00e4usser M, Schmidt J, Toyka KV, Gold R. Glukokortikosteroid-Therapie bei Optikusneuritis und Multipler Sklerose. Evidenz aus klinischen Studien und praktische Empfehlungen. Nervenarzt. 2001;72:577\u201389.","journal-title":"Nervenarzt"},{"key":"927_CR5","doi-asserted-by":"crossref","unstructured":"Burton JM, O'Connor PW, Hohol M, Beyene J. Oral versus intravenous steroids for treatment of relapses in multiple sclerosis. Cochrane Database Syst Rev. 2009:CD006921.","DOI":"10.1002\/14651858.CD006921.pub2"},{"key":"927_CR6","volume":"12","author":"JM Burton","year":"2012","unstructured":"Burton JM, O'Connor PW, Hohol M, Beyene J. Oral versus intravenous steroids for treatment of relapses in multiple sclerosis. Cochrane Database Syst Rev. 2012;12:CD006921.","journal-title":"Cochrane Database Syst Rev"},{"key":"927_CR7","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1136\/jnnp.56.11.1219","volume":"56","author":"SM Alam","year":"1993","unstructured":"Alam SM, Kyriakides T, Lawden M, Newman PK. Methylprednisolone in multiple sclerosis: a comparison of oral with intravenous therapy at equivalent high dose. J Neurol Neurosurg Psychiatry. 1993;56:1219\u201320.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"927_CR8","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/S0140-6736(96)06453-7","volume":"349","author":"D Barnes","year":"1997","unstructured":"Barnes D, Hughes RA, Morris RW, et al. Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet. 1997;349:902\u20136.","journal-title":"Lancet"},{"key":"927_CR9","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1212\/WNL.36.2.238","volume":"36","author":"L Durelli","year":"1986","unstructured":"Durelli L, Cocito D, Riccio A, et al. High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: clinical-immunologic correlations. Neurology. 1986;36:238\u201343.","journal-title":"Neurology"},{"key":"927_CR10","volume":"4","author":"G Filippini","year":"2000","unstructured":"Filippini G, Brusaferri F, Sibley WA, et al. Corticosteroids or ACTH for acute exacerbations in multiple sclerosis. Cochrane Database Syst Rev. 2000;(4):CD001331.","journal-title":"Cochrane Database Syst Rev."},{"key":"927_CR11","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1212\/WNL.51.2.529","volume":"51","author":"F Sellebjerg","year":"1998","unstructured":"Sellebjerg F, Frederiksen JL, Nielsen PM, Olesen J. Double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS. Neurology. 1998;51:529\u201334.","journal-title":"Neurology"},{"key":"927_CR12","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/1742-2094-9-80","volume":"9","author":"MJ Koziolek","year":"2012","unstructured":"Koziolek MJ, Tampe D, B\u00e4hr M, et al. Immunoadsorption therapy in patients with multiple sclerosis with steroid-refractory optical neuritis. J Neuroinflammation. 2012;9:80.","journal-title":"J Neuroinflammation"},{"key":"927_CR13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000332397","volume":"33","author":"C Trebst","year":"2012","unstructured":"Trebst C, Bronzlik P, Kielstein JT, Schmidt BMW, Stangel M. Immunoadsorption therapy for steroid-unresponsive relapses in patients with multiple sclerosis. Blood Purif. 2012;33:1\u20136.","journal-title":"Blood Purif"},{"key":"927_CR14","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.atherosclerosissup.2012.10.025","volume":"14","author":"F Heigl","year":"2013","unstructured":"Heigl F, Hettich R, Arendt R, Durner J, Koehler J, Mauch E. Immunoadsorption in steroid-refractory multiple sclerosis: clinical experience in 60 patients. Atheroscler Suppl. 2013;14:167\u201373.","journal-title":"Atheroscler Suppl"},{"key":"927_CR15","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1159\/000224630","volume":"28","author":"C Trebst","year":"2009","unstructured":"Trebst C, Reising A, Kielstein JT, Hafer C, Stangel M. Plasma exchange therapy in steroid-unresponsive relapses in patients with multiple sclerosis. Blood Purif. 2009;28:108\u201315.","journal-title":"Blood Purif"},{"key":"927_CR16","doi-asserted-by":"crossref","first-page":"e0134583","DOI":"10.1371\/journal.pone.0134583","volume":"10","author":"J Ehler","year":"2015","unstructured":"Ehler J, Koball S, Sauer M, et al. Response to therapeutic plasma exchange as a rescue treatment in clinically isolated syndromes and acute worsening of multiple sclerosis: a retrospective analysis of 90 patients. PLoS One. 2015;10:e0134583.","journal-title":"PLoS One"},{"key":"927_CR17","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.clinthera.2013.02.027","volume":"35","author":"JE Meca-Lallana","year":"2013","unstructured":"Meca-Lallana JE, Hern\u00e1ndez-Clares R, Le\u00f3n-Hern\u00e1ndez A, Genov\u00e9s Aleixandre A, Cacho P\u00e9rez M, Mart\u00edn-Fern\u00e1ndez JJ. Plasma exchange for steroid-refractory relapses in multiple sclerosis: an observational, MRI pilot study. Clin Ther. 2013;35:474\u201385.","journal-title":"Clin Ther"},{"key":"927_CR18","volume-title":"Leitlinie Diagnostik und Therapie der Multiplen Sklerose. 5., vollst. \u00fcberarb. Aufl","author":"R Gold","year":"2012","unstructured":"Gold R. Leitlinie Diagnostik und Therapie der Multiplen Sklerose. 5., vollst. \u00fcberarb. Aufl. Stuttgart: Thieme; 2012."},{"key":"927_CR19","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1177\/1352458513508835","volume":"20","author":"C Ramo-Tello","year":"2014","unstructured":"Ramo-Tello C, Grau-L\u00f3pez L, Tintor\u00e9 M, et al. A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS. Mult Scler. 2014;20:717\u201325.","journal-title":"Mult Scler"},{"key":"927_CR20","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/S0140-6736(15)61137-0","volume":"386","author":"E Page Le","year":"2015","unstructured":"Le Page E, Veillard D, Laplaud DA, et al. Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial. Lancet. 2015;386:974\u201381.","journal-title":"Lancet"},{"key":"927_CR21","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1212\/WNL.50.6.1833","volume":"50","author":"RL Oliveri","year":"1998","unstructured":"Oliveri RL, Valentino P, Russo C, et al. Randomized trial comparing two different high doses of methylprednisolone in MS: a clinical and MRI study. Neurology. 1998;50:1833\u20136.","journal-title":"Neurology"},{"issue":"Pt 7","key":"927_CR22","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/brain\/123.7.1431","volume":"123","author":"J Schmidt","year":"2000","unstructured":"Schmidt J, Gold R, Sch\u00f6nrock L, Zettl UK, Hartung HP, Toyka KV. T-cell apoptosis in situ in experimental autoimmune encephalomyelitis following methylprednisolone pulse therapy. Brain. 2000;123(Pt 7):1431\u201341.","journal-title":"Brain"},{"key":"927_CR23","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1111\/j.1468-1331.2005.01352.x","volume":"12","author":"F Sellebjerg","year":"2005","unstructured":"Sellebjerg F, Barnes D, Filippini G, et al. EFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapses. Eur J Neurol. 2005;12:939\u201346.","journal-title":"Eur J Neurol"},{"key":"927_CR24","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1212\/WNL.58.2.169","volume":"58","author":"DS Goodin","year":"2002","unstructured":"Goodin DS, Frohman EM, Garmany GP, et al. Disease modifying therapies in multiple sclerosis: report of the therapeutics and technology assessment Subcommittee of the American Academy of neurology and the MS Council for clinical practice guidelines. Neurology. 2002;58:169\u201378.","journal-title":"Neurology"},{"key":"927_CR25","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1212\/WNL.0b013e31818f3d8b","volume":"71","author":"DS Goodin","year":"2008","unstructured":"Goodin DS. Disease-modifying therapy in multiple sclerosis: update and clinical implications. Neurology. 2008;71:S8\u201313.","journal-title":"Neurology."},{"key":"927_CR26","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1159\/000117038","volume":"34","author":"L Mantia La","year":"1994","unstructured":"La Mantia L, Eoli M, Milanese C, et al. Double trial of dexamethasone versus methylprednisolone in multiple sclerosis acute relapses. Eur Neurol. 1994;34:199\u2013203.","journal-title":"Eur Neurol"},{"key":"927_CR27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/WNL.44.1.1","volume":"44","author":"MJ Kupersmith","year":"1994","unstructured":"Kupersmith MJ, Kaufman D, Paty DW, et al. MEgadose corticosteroids in multiple sclerosis. Neurology. 1994;44:1\u20134.","journal-title":"Neurology"},{"key":"927_CR28","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/1096-9926(200012)62:6<385::AID-TERA5>3.0.CO;2-Z","volume":"62","author":"L Park-Wyllie","year":"2000","unstructured":"Park-Wyllie L, Mazzotta P, Pastuszak A, et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology. 2000;62:385\u201392.","journal-title":"Teratology"},{"key":"927_CR29","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00115-014-4239-8","volume":"86","author":"F Hoffmann","year":"2015","unstructured":"Hoffmann F, Kraft A, Heigl F, et al. Tryptophan-Immunadsorption bei Multipler Sklerose und Neuromyelitis optica: Therapieoption bei akuten Sch\u00fcben in der Schwangerschaft und Stillphase. Nervenarzt. 2015;86:179\u201386.","journal-title":"Nervenarzt"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-017-0927-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,7]],"date-time":"2017-08-07T05:44:46Z","timestamp":1502084686000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-017-0927-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,7]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["927"],"URL":"https:\/\/doi.org\/10.1186\/s12883-017-0927-x","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,7]]},"article-number":"151"}}